This study was approved by the Research Review Board at Wenzhou Medical University. Each subject was treated in accordance with the tenets of the Declaration of Helsinki, and all the patients signed informed consent. The surgeries were performed at the Refractive Surgery Center of The Eye Hospital of Wenzhou Medical University. For inclusion into the study, patients had to be between 20 and 30 years old and have a stable refractive error during the previous 2 years (progressing by less than 0.5 diopters annually). They also had to have a spherical equivalent (SE) refraction between −1.00 diopters and −8.00 diopters and astigmatism of less than −2.00 diopters. The exclusion criteria were active ocular or systemic diseases, severe dry eye syndrome, a residual corneal stromal bed of less than 280 μm, preoperative best-corrected visual acuity less than 20/20, and postoperative enhancement.
All patients underwent the following sequential examinations during screening: anterior segment OCT, visual acuity, manifest refraction, corneal topography, noncontact tonometry, slit-lamp biomicroscopy, funduscopy, and pachymetry. Corneal flap creation by microkeratome was performed by Shihao Chen, and flap creation by femtosecond laser was performed by Ye Yu. In the microkeratome group, a Moria II microkeratome (Moria, Antony, France) was used to create the corneal flaps, and all of the flap hinges were located at the nasal cornea. In the femtosecond laser group, a 60-KHz IntraLase FS Laser (Abbott Medical Optics, Inc., Santa Ana, CA, USA) was used to create the corneal flaps, and all of the flap hinges were located at nasal cornea, as well. A Zeiss Mel-80 scan flying-spot excimer laser (Carl Zeiss Meditec-Aesclepion, Jena, Germany) was used to perform further ablation in both groups. Patients in both groups were treated with corticosteroid eyedrops (Fluorometholone 0.1%; Allergan, Inc., Irvine, CA, USA) four times daily during the first week after surgery, then tapered over the following 4 weeks. Patients in both groups were also instructed to use artificial tears (Refresh Plus; Allergan, Inc.) four times daily for at least the first month after surgery.